Given the adverse acute health effects of androstenedione and the lack
of knowledge of its long-term effects, a critical question arises:
"Why is over-the-counter sale of this androgenic steroid hormone
permitted, even to children?" In part, the answer lies with 2 federal
laws: the Anabolic Steroid Control Act of 199016 and the
Dietary Supplement Health and Education Act of 1994.17 The
Anabolic Steroid Control Act classified testosterone and a number of
its derivatives as Schedule III drugs under the Controlled Substance
Act. However, androstenedione is not one of the substances specifically
designated by the Act. To so designate androstenedione, and, therefore,
force its removal from store shelves, the following criteria must be
met: (1) the substance must have a molecular structure related to
testosterone; (2) the substance must have a pharmacology related to
testosterone; (3) the substance cannot be an estrogen, progestin, or
corticosteroid; and (4) the substance must promote muscle growth. While
there is a reasonable amount of evidence to support, at least in part,
criteria 1 through 3,1 ,18 the findings presented by King
and colleagues show that androstenedione does not meet the fourth
criterion. However, based on a comparison of the different effects of
oral vs injectable testosterone,1 one could legitimately
hypothesize that if androstenedione were administered by injection
at a substantially higher dose, muscle growth would be observed.